A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients

Authors

Anne C Goldberg, Washington University School of Medicine in St. Louis
Richard L Dunbar, University of Pennsylvania
Linda Hemphill, Harvard University
Stephan P Babirak, Metabolic Leader, LLC
Gerald Wilson, Regeneron Pharmaceuticals, Inc.
Michael Wooten, Regeneron Pharmaceuticals, Inc.
Mohamed Iydroose, Regeneron Pharmaceuticals, Inc.
Kelley Dacus, Regeneron Pharmaceuticals, Inc.
Heather Minchew, University of Kansas
Julie-Ann Dutton, University of Kansas
Patrick M Moriarty, University of Kansas

Journal

Journal of Clinical Lipidology

Publication Date

11-1-2020

Volume

14

Issue

6

First Page

818

Last Page

824

Document Type

Open Access Publication

DOI

10.1016/j.jacl.2020.08.005

Rights and Permissions

Goldberg AC, Dunbar RL, Hemphill L, Babirak SP, Wilson G, Wooten M, Iydroose M, Dacus K, Minchew H, Dutton JA, Moriarty PM. A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients. J Clin Lipidol. 2020 Nov-Dec;14(6):818-824. doi: 10.1016/j.jacl.2020.08.005. Copyright 2020 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Goldberg, Anne C; Dunbar, Richard L; Hemphill, Linda; Babirak, Stephan P; Wilson, Gerald; Wooten, Michael; Iydroose, Mohamed; Dacus, Kelley; Minchew, Heather; Dutton, Julie-Ann; and Moriarty, Patrick M, "A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients." Journal of Clinical Lipidology. 14, 6. 818 - 824. (2020).
https://digitalcommons.wustl.edu/oa_4/1144